---
figid: PMC4490961__nihms684782f2
figtitle: Interaction of the TFF2-CXCR4 axis with the active RAS-RAF-MEK-ERK pathway
  in the serrated pathway of colorectal cancer
organisms:
- NA
pmcid: PMC4490961
filename: nihms684782f2.jpg
figlink: /pmc/articles/PMC4490961/figure/F2/
number: F2
caption: Interaction of the TFF2-CXCR4 axis with the active RAS-RAF-MEK-ERK pathway
  in the serrated pathway of colorectal cancer. Presently, cetuximab is an EGFR inhibitor
  approved for colorectal cancer. Clinical trials for the use of vemurafenib for BRAF
  V600E are ongoing. ERK refers to extracellular signal-regulated kinases.
papertitle: TFF2-CXCR4 Axis is Associated with BRAF V600E Colon Cancer.
reftext: Manish K. Gala, et al. Cancer Prev Res (Phila). ;8(7):614-619.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.956452
figid_alias: PMC4490961__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4490961__F2
ndex: 6b05757c-deb8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4490961__nihms684782f2.html
  '@type': Dataset
  description: Interaction of the TFF2-CXCR4 axis with the active RAS-RAF-MEK-ERK
    pathway in the serrated pathway of colorectal cancer. Presently, cetuximab is
    an EGFR inhibitor approved for colorectal cancer. Clinical trials for the use
    of vemurafenib for BRAF V600E are ongoing. ERK refers to extracellular signal-regulated
    kinases.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TFF2
  - EGF
  - EGFR
  - CXCR4
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
